EUVIMEDEUVIMED entdecken
Übersichtsarbeit

All we need to know about lipoprotein(a)

Courtney Bess, Anurag Mehta, Parag H Joshi

Progress in Cardiovascular Diseases · 2024

DOI: 10.1016/j.pcad.2024.05.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2024. Verfasst von Courtney Bess und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern, Dallas, TX, United States of America; Parkland Health and …. Hauptthemen laut MEDLINE: Lipoprotein(a), Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipoprotein(a) [Lp(a)], a genetically determined macromolecular complex, is independently and causally associated with atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis via proposed proinflammatory, prothrombotic, and proatherogenic mechanisms. While Lp(a) measurement standardization issues are being resolved, several guidelines now support testing Lp(a) at least once in each adult's lifetime for ASCVD risk prediction which can foster implementation of more aggressive primary or secondary prevention therapies. Currently, there are several emerging targeted Lp(a) lowering therapies in active clinical investigation for safety and cardiovascular benefit among both primary and secondary prevention populations. First degree relatives of patients with high Lp(a) should be encouraged to undergo cascade screening. Primary prevention patients with high Lp(a) should consider obtaining a coronary calcium score for further risk estimation and to guide further ASCVD risk factor management including consideration of low dose aspirin therapy. Secondary prevention patients with high Lp(a) levels should consider adding PCSK9 inhibition to statin therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)BiomarkersHumansRisk AssessmentAtherosclerosisRisk FactorsSecondary PreventionHeart Disease Risk Factors

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseLipidsLipoprotein(a)

Substanzen

Lipoprotein(a)BiomarkersLPA protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern, Dallas, TX, United States of America; Parkland Health and Hospital System, Dallas, TX, United States of America.
  • VCU Health Pauley Health Center, Richmond, VA, United States of America.
  • Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern, Dallas, TX, United States of America; Parkland Health and Hospital System, Dallas, TX, United States of America. Electronic addr…

Zitieren

APA

Bess, C., Mehta, A., & Joshi, P. H. (2024). All we need to know about lipoprotein(a). Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.05.007

Vancouver

Bess C, Mehta A, Joshi PH. All we need to know about lipoprotein(a). Progress in Cardiovascular Diseases. 2024. doi:10.1016/j.pcad.2024.05.007

BibTeX
@article{Bess2024,
  author = {Bess, Courtney and Mehta, Anurag and Joshi, Parag H},
  title = {All we need to know about lipoprotein(a)},
  journal = {Progress in Cardiovascular Diseases},
  year = {2024},
  doi = {10.1016/j.pcad.2024.05.007}
}
Kostenlos starten →